1. United Kingdom Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
EKF Diagnostics Holdings plc

EKF Diagnostics Holdings plc

EKDHF
EKF Diagnostics Holdings plcUS flagOther OTC
0.35
USD
- -
- -
149.28MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
0.12
0.1
0.07
0.09
0.09
0.09
0.1
0.14
0.18
0.15
0.12
0.11
0.12
Basic EPS, GAAP
- -
-0.01
-0.09
- -
0.01
0.02
0.01
0.02
0.03
-0.02
0.01
0.01
- -
Free Cash Flow per Basic Share
- -
-0.02
-0.02
0.02
0.01
0.01
0.01
0.02
0.01
0.01
- -
0.02
0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
0.01
0.01
0.01
0.01
- -
- -
Book Value per Share
- -
-0.01
-0.1
-0.09
0.12
0.12
0.13
0.15
0.17
0.12
0.12
0.13
0.13
Tangible Book Value per Share
0.02
-0.02
0.01
0.03
0.04
0.05
0.07
0.09
0.12
0.09
0.08
0.1
0.09
Basic Weighted Avg Shares
272
380
422
446
463
457
454
455
457
457
454
454
448
Sales/Revenue/Turnover
32
37
30
39
42
43
45
65
82
67
53
50
52
Operating Margin (%)
7.55
-5.23
-47.76
-0.85
11.37
28.67
12.88
25.89
26.69
2.67
8.24
12.52
13.53
Depreciation Expense
4
5
8
5
5
4
4
5
6
7
5
5
5
Net Income, GAAP
-1
-6
-37
- -
3
10
4
11
16
-10
2
6
2
Effective Tax Rate (%)
247.12
- -
- -
- -
31.74
15.34
28.74
25.86
24.62
- -
- -
- -
64.28
Profit Margin (%)
-3.54
-15.33
-123.56
-0.05
6.53
23.76
8.19
17.03
19.37
-15.16
4.47
12.44
4.12
Working Capital
6
7
-3
7
9
10
14
25
34
20
16
22
23
LT Debt
2
2
1
1
1
1
1
1
2
1
1
1
1
Total Equity
41
87
47
61
60
64
71
78
95
75
68
73
70
Return on Invested Capital (%)
-8.06
- -
- -
- -
4.91
15.96
5.81
15.99
18.15
- -
- -
- -
3.36
Return on Capital (%)
-80.24
- -
- -
- -
22.93
17.3
5.71
16.37
20.47
- -
- -
- -
2.93
Return on Common Equity (%)
- -
- -
- -
- -
- -
18.05
6.24
17.26
21.57
-14.86
4.26
11.06
3.66

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.12%
-1.07%
-4.01%
Free Cash Flow
-189.49%
-393.24%
-32.66%
Net Income, GAAP
-1,501.73%
-29%
-66%
Sales/Revenue/Turnover
7.33%
-3.22%
2.73%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
53
2024
- -
- -
- -
- -
50
2025
- -
- -
- -
- -
52

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.01
2024
- -
- -
- -
- -
0.01
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.01
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Gavin Joseph Jones
Full Time Employees
301
Sector
Healthcare
Industry
Medical - Devices
Address
Avon House Cardiff United Kingdom CF64 2EZ
IPO Date
Nov 17, 2014
Website
ekfdiagnostics.com
Similar Companies
Apyx Medical Corporation (BVX)
iRhythm Technologies, Inc. (IRTC)
Olympus Corporation (OCPNF)
EKF Diagnostics Holdings plc (EKDHF)
Cytosorbents Corporation (CTSO)
GN Store Nord A/S (GN.CO)
Business
EKF Diagnostics Holdings plc is an AIM-listed diagnostics and biotechnology company that develops, manufactures and distributes point-of-care testing devices, central laboratory analyzers and reagents, and life sciences products including enzymes and contract fermentation services; it offers analyzers for hemoglobin, hematocrit, HbA1c, glucose, lactate and beta-hydroxybutyrate (β-HB), such as Hemo Control, Diaspect Tm, Biosen, Quo-Test and Quo-Lab, alongside β-HB LiquiColor reagents, clinical chemistry tests and custom kits for research, biotech and pharmaceutical applications. Founded in 1990 and headquartered in Penarth, near Cardiff, United Kingdom, the company operates manufacturing facilities in the United States and Germany, with a presence in Russia, and distributes products to over 120 countries worldwide targeting hospitals, clinics, blood banks, laboratories and industrial users. In recent developments, EKF reports record hematology analyzer sales with a 60% production increase in the first half of 2025 versus the prior year, secures post-period contract wins worth approximately €4.65 million for hemoglobin analyzers and consumables in Latin America and Africa to be delivered over 12 to 24 months, advances production capacity expansion plans by a further 30% at its Barleben site, achieves 12% growth in β-HB sales driven by partner conversions to own-label products, completes a circa £1 million share buyback acquiring 4.6 million shares, and progresses a five-year strategic plan targeting over £80 million in revenues and number one positions in point-of-care hematology and ketone testing by 2029, while winding down low-margin clinical chemistry lines.

Company News

APIChatGPT

  • defenseworld.net

    EKF Diagnostics (EKDHF) Projected to Post Earnings on Tuesday

  • defenseworld.net

    EKF Diagnostics (OTCMKTS:EKDHF) Stock Price Up 0.9% – Should You Buy?

  • seekingalpha.com

    EKF Diagnostics Holdings plc (EKDHF) Q2 2025 Earnings Call Transcript